MedTrace Logo

Probiotics Improve Adult Allergic Rhinitis and Regulate Gut Microbiota

NCT06885346 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-03-20

No results posted yet for this study

Summary

Assessing the clinical efficacy of weizmannia coagulans BC99 in alleviating allergic rhinitis symptoms, improving gut microbiota, and reducing adverse reactions in patients.

Conditions

  • Allergic Rhinitis

Interventions

DIETARY_SUPPLEMENT

Probiotic

The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.

DIETARY_SUPPLEMENT

Placebo

The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.

Sponsors & Collaborators

  • Wecare Probiotics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-02
Primary Completion
2024-12-28
Completion
2025-02-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06885346 on ClinicalTrials.gov